ProMIS
This person does not yet have a bio.Content by ProMIS
| 5 min read
Discovery of antibodies highly selective for toxic α-synuclein conformations may require more than just classical methods if pharma and life sciences want to make faster progress against Parkinson's disease
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
